Industry Bodies Respond To EU Ministers' Plans To Address 'Balance' In Pharmaceutical System
This article was originally published in SRA
In response to news that the European Commission is to conduct an analysis of the effects of regulatory incentives such as data and market exclusivity on innovation, drug pricing, access to medicines and generic entry, two of the key pharmaceutical industry bodies, Medicines for Europe and EFPIA, have come up with their own proposals for engaging with the EU member states to ensure the long-term sustainability of national healthcare systems.
You may also be interested in...
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.
Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir
The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.